lifestyle.capitolhilltimes.com

Author: ABLi Therapeutics

ABLi Therapeutics to Present at the Citizens Life Sciences Conference

March 5, 2026
ABLi Therapeutics Announces Publication of the Final Results from the Phase 2 ‘201 Trial’ Evaluating Risvodetinib for the Treatment of Parkinson’s Disease

February 20, 2026
ABLi Therapeutics Completes Collaboration Agreement with The Michael J. Fox Foundation to include Risvodetinib in Path to Prevention Platform Trial

January 27, 2026